Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 7
Submit an article Journal homepage
247
Views
31
CrossRef citations to date
0
Altmetric
Drug Evaluations

IC51 Japanese Encephalitis vaccine

Herwig Kollaritsch Medical University Vienna, Centre for Physiology and Pathophysiology, Institute of Specific Prophylaxis and Tropical Medicine, Kinderspitalgasse 15, A-1090 Vienna, Austria +43 1 40490 64865; +43 1 40490 64899; [email protected]
, MD,
Maria Paulke-Korinek Medical University Vienna, Centre for Physiology and Pathophysiology, Institute of Specific Prophylaxis and Tropical Medicine, Kinderspitalgasse 15, A-1090 Vienna, Austria +43 1 40490 64865; +43 1 40490 64899; [email protected]
, MD MSc &
Katrin Dubischar-Kastner Senior Manager, Clinical Research, Intercell AG, Campus Vienna Biocenter 3, A-1030 Vienna, Austria
, MSc
Pages 921-931 | Published online: 15 Jun 2009

Bibliography

  • Thiel H-J, Collett MS, Gould EA, et al. Index of Viruses – Flaviviridae ICTVdB – The Universal Virus Database, version 4: Büchen-Osmond C, Editor, Columbia University, New York, USA 2006. Available from: http://www.ncbi.nlm.nih.gov/ICTVdb/Ictv/fs_index.htm [Last accessed 26 May 2009]
  • Solomon T, Ni H, Beasley DWC, et al. Origin and evolution of Japanese encephalitis virus in southeast Asia. J Virol 2003;77(5):3091-8
  • Sumiyoshi H, Mori C, Fuke I, et al. Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology 1987;161(2):497-510
  • Ma SP, Yoshida Y, Makino Y, et al. Short report: A major genotype of Japanese encephalitis virus currently circulating in Japan. Am J Trop Med Hyg 2003;69(2):151-4
  • Oya A, Kurane I. Japanese encephalitis for a reference to international travelers. J Travel Med 2007;14(4):259-68
  • Konishi E, Yamaoka M, Khin Sane W, et al. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J Virol 1999;73(7):5527-34
  • Beasley DW, Li L, Suderman MT, et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 2004;22(27-28):3722-6
  • Chiou SS, Tsai KH, Huang CG, et al. High antibody prevalence in an unconventional ecosystem is related to circulation of a low-virulent strain of Japanese encephalitis virus. Vaccine 2007;25(8):1437-43
  • Halstead SB, Jacobson J. Japanese Encephalitis Vaccines. In: Plotkin SA, Orenstein WA, Offit P, editors, Vaccines. Fourth edition: Philadelphia: Saunders Elsevier, 2008
  • Sunish IP, Reuben R. Factors influencing the abundance of Japanese encephalitis vectors in ricefields in India – I. Abiotic. Med Vet Entomol 2001;15(4):381-92
  • Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993;42(RR-1):1-15
  • Gould DJ, Byrne RJ, Hayes DE. Experimental infection of horses with Japanese encephalitis virus by mosquito bite. Am J Trop Med Hyg 1964;13(5):742-6
  • Japanese Encephalitis vaccines: WHO position paper. Wkly Epidemiol Rec 2006;81:331-40
  • WHO. Japanese encephalitis. Available from: http://www.who.int/vaccine_research/diseases/vector/en/index1.html [Last accessed 26 May 2009]
  • Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: Minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000;18(Suppl 2):1-25
  • Hanna J, Ritchie S, Phillips D, et al. Japanese encephalitis in north Queensland, Australia, 1998. Med J Aust 1999;170(11):533-6
  • Beasley DW, Lewthwaite P, Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 2008;8(1):95-106
  • SEARO WHO. Immunization and Vaccine Development, Japanese Encephalitis. 2005; Available from: http://www.searo.who.int/en/section1226/section2073.asp [Last accessed 26 May 2009]
  • Solomon T. Control of Japanese encephalitis – within our grasp? N Engl J Med 2006;355(9):869-71
  • WHO. Report of the Bi-Regional Meeting on Japanese Encephalitis, 2005. Available from: http://www.wpro.who.int/NR/rdonlyres/A62D4A75-0C28-4093-95CF-555CE379C469/0/MTGRPT_BiregionalJE2005.pdf [Last accessed 26 May 2009]
  • Gajanana A, Thenmozhi V, Samuel PP, Reuben R. A community-based study of subclinical flavivirus infections in children in an area of Tamil Nadu, India, where Japanese encephalitis is endemic. Bull World Health Organ 1995;73(2):237-44
  • Steinhoff MC. Japanese encephalitis: a Chinese solution? Lancet 1996;347(9015):1570-1
  • Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 2008;371(9611):500-9
  • Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003;361(9360):821-6
  • Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007;370(9602):1847-53
  • Oya A. Japanese encephalitis vaccine. Acta Paediatr Jpn 1988;30(2):175-84
  • Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev 2007;3:1-44
  • Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev Vaccines 2008;7(5):689-93
  • Sugawara K, Nishiyama K, Ishikawa Y, et al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 2002;30(4):303-14
  • Sakaguchi M, Miyazawa H, Inouye S. Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines. Allergy 2001;56(6):536-9
  • Hanna JN, Smith GA, Mcculloch BG, et al. An assessment of the interval between booster doses of Japanese encephalitis vaccine in the Torres Strait. Aust N Z J Public Health 2005;29(1):44-7
  • Abe M, Okada K, Hayashida K, et al. Duration of neutralizing antibody titer after Japanese encephalitis vaccination. Microbiol Immunol 2007;51(6):609-16
  • Kollaritsch H. Japan-B-Encephalitis. In: Kollaritsch H, Wiedermann G, editors, Leitfaden für Schutzimpfungen. Wien: Springer Verlag, 2000
  • Xin YY, Ming ZG, Peng GY, et al. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg 1988;39(2):214-7
  • Eckels KH, Yu YX, Dubois DR, et al. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 1988;6(6):513-8
  • WHO. Global Advisory Committee on Vaccine Safety, 9–10 June 2005. Wkly Epidemiol Rec 2005;28(80):242-3
  • Yaïch M, Jacobson J. Satellite symposium on Japanese encephalitis and dengue vaccine research. Proceedings of the seventh global vaccine research forum and parallel satellite symposia, 3-6 December 2006, 2007. Available from: http://whqlibdoc.who.int/hq/2007/WHO_IVB_07.10_eng.pdf [Last accessed 26 May 2009]
  • Liu ZL, Hennessy S, Strom BL, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 1997;176(5):1366-9
  • Hennessy S, Liu Z, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996;347(9015):1583-6
  • Tandan JB, Ohrr H, Sohn YM, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization. Vaccine 2007;25(27):5041-5
  • Gatchalian S, Yao Y, Zhou B, et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 2008;26(18):2234-41
  • Applied Strategies. GAVI Vaccine Investment Strategy. Landscape Analysis - Japanese Encephalitis 2008. Available from: http://www.gavialliance.org/ resources/18_JE_Landscape_Jun08.pdf [Last accessed 26 May 2009]
  • Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003;188(8):1213-30
  • Solomon T. New vaccines for Japanese encephalitis. Lancet Neurol 2008;7(2):116-8
  • Lyons A, Kanesa-Thasan N, Kuschner RA, et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 2007;25(17):3445-53
  • Srivastava AK, Putnak JR, Lee SH, et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 2001;19(31):4557-65
  • Available from: http://clinicaltrials.gov/ct2/results?term=IC51
  • Hombach J, Solomon T, Kurane I, et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005;23(45):5205-11
  • Schuller E, Klade CS, Wolfl G, et al. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase 3 study. Vaccine 2009;27(15):2188-93
  • Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008;26(34):4382-6
  • Schuller E, Klade CS, Heinz FX, et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008;26(48):6151-6
  • Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988;319(10):608-14
  • Hammon WM, Sather GE. Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. Am J Trop Med Hyg 1973;22(4):524-34
  • Intercell. Intercell for Vaccperts. Available from: http://www.intercell.com/main/forvaccperts/products/ japanese-encephalitis-vaccine/ [Last accessed 26 May 2009]
  • Duggan ST, Plosker GL. Japanese Encephalitis Vaccine (Inactivated, Adsorbed) [IXIARO]. Drugs 2009;69(1):115-22
  • Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008;198(4):493-9
  • Dubischar-Kastner K, Kaltenboeck A, Schuller E, et al. Six months safety of a vero-cell derived Japanese Encephalitis vaccine, IXIARO, IC51, across phase 3 trials and in a long term follow up cohort [abstract 836]. Proceedings of ASTMH Annual Meeting; Dec 7-11, 2008; New Orleans, USA.
  • Rendi-Wagner P, Kundi M, Zent O, et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine 2004;23(4):427-34
  • Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am 2003;23(4):665-97
  • Ohtaki E, Matsuishi T, Hirano Y, Maekawa K. Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains). J Neurol Neurosurg Psychiatry 1995;59(3):316-7
  • Nazareth B, Levin J, Johnson H, Begg N. Systemic allergic reactions to Japanese encephalitis vaccines. Vaccine 1994;12(7):666
  • Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 1991;337(8748):1044
  • Presseportal 2006. Available from: http://www.presseportal.de [Last accessed 16 April 2009]
  • Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 2002;35(2):183-8
  • Steffen R, Connor BA. Vaccines in travel health: from risk assessment to priorities. J Travel Med 2005;12(1):26-35
  • Wittesjo B, Eitrem R, Niklasson B, et al. Japanese encephalitis after a 10-day holiday in Bali. Lancet 1995;345(8953):856-7
  • Lehtinen VA, Huhtamo E, Siikamaki H, Vapalahti O. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol 2008;43(1):93-5
  • Caramello P, Canta F, Balbiano R, et al. A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader? J Travel Med 2007;14(5):346-8
  • Berg SW, Mitchell BS, Hanson RK, et al. Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clin Infect Dis 1997;24(2):265-6
  • Jong EC, Tsai TF. Reassessing the risk of Japanese Encephalitis in travelers: lessons from case reports. Proceedings of ASTMH Annual Meeting; Dec 7-11, 2008; New Orleans, USA: Amended abstract 2945

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.